Su questa pagina
LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 6, 2026
$1,82
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$1,11minimo 52 sett.
$2,68massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$813M
P/E (TTM)
-12.1
EPS (TTM)
$-0.15
Ricavi (TTM)
$41M
i tuoi badge
Intervallo 52 sett.
$1–$3
Rating Analisti
BUY
Prezzo Obiettivo
$5
P/E
-12.1
ROE
-40.2%
Margine di Profitto Netto
-147.4%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
LXRX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$1.82
Capitalizzazione di Mercato (MRQ)
$813M
P/E (TTM)
-12.1
EPS (TTM)
$-0.15
Ricavi (TTM)
$41M
ROE (TTM)
-40.2%
D/E Debito/Patrimonio (MRQ)
0.3
Intervallo 52 sett.
$1–$3
LXRX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 21 Maggio 2015 | 1-for-7 | Inverso |
Informazioni su Lexicon Pharmaceuticals, Inc. - Common Stock Panoramica della società da Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of different compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaPharmaceuticals
dipendenti81
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$50M2016-12-31 → 2025-12-31
EPS$-0.142017-12-31 → 2025-12-31
Flusso di cassa libero$-68M2016-12-31 → 2025-12-31
Margine netto-147.4%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | LXRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -12.1media 5 anni ≈-4.2 | ≈-4.2 | · | · | |
| P/S (TTM) | 19.6media 5 anni ≈1530.9 | ≈1530.9 | 6.6 | Sopravvalutato | |
| P/B (MRQ) | 4.7media 5 anni ≈4.1 | ≈4.1 | 3.8 | Sopravvalutato | |
| EV / EBITDA (TTM) | -12.5 | · | · | · | |
| Price / FCF (Prezzo / FCF) | -9.8media 5 anni ≈-5.6 | ≈-5.6 | · | · | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -9.8media 5 anni ≈-5.7 | ≈-5.7 | · | · | |
| EV / Ricavi (TTM) | 16.3 | · | · | · | |
| EV / FCF | -9.2 | · | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 10.6media 5 anni ≈6.7 | ≈6.7 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | LXRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | -131.4%media 5 anni ≈-23342.3% | ≈-23342.3% | -78.2% | Debole | |
| Margine EBITDA (TTM) | -130.3%media 5 anni ≈-23251.5% | ≈-23251.5% | -59.5% | Debole | |
| Margine di Profitto Netto (TTM) | -147.4%media 5 anni ≈-23649.3% | ≈-23649.3% | -23.7% | Debole | |
| ROA (TTM) | -25.7%media 5 anni ≈-58.7% | ≈-58.7% | -34.1% | Di prim'ordine | |
| ROE (TTM) | -40.2%media 5 anni ≈-105.9% | ≈-105.9% | 50.0% | Debole |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | LXRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | 0.3media 5 anni ≈0.6 | ≈0.6 | 0.0 | Debito elevato | |
| Rapporto corrente (MRQ) | 13.4media 5 anni ≈5.2 | ≈5.2 | 4.3 | Liquidità elevata | |
| Quick Ratio (MRQ) | 13.1media 5 anni ≈5.1 | ≈5.1 | 2.0 | Liquidità elevata | |
| Debito a lungo termine / Patrimonio netto (MRQ) | 0.3media 5 anni ≈0.7 | ≈0.7 | 0.0 | Debito elevato |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | LXRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 60.2%media 5 anni ≈631.2% | ≈631.2% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 610.2%media 5 anni ≈305.9% | ≈305.9% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 15.7% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | LXRX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.2media 5 anni ≈0.1 | ≈0.1 | 0.4 | Debole | |
| Inventory Turnover (Rotazione delle scorte) | 1.1media 5 anni ≈1.2 | ≈1.2 | 2.1 | Debole | |
| Receivables Turnover (Rotazione dei crediti) | 17.0media 5 anni ≈8.3 | ≈8.3 | 3.5 | Di prim'ordine | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$614.9K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
48.2%
Prossimo report
Nov 13, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 4, 2026 | $-0.07 | $-0.05 | -36.7% |
| 31 Marzo 2026 | Mag 11, 2026 | $0.00 | $-0.04 | 100.0% |
| 31 Dicembre 2025 | $-0.04 | $-0.07 | 43.2% | |
| 30 Settembre 2025 | $-0.04 | $-0.07 | 40.6% | |
| 30 Giugno 2025 | $0.01 | $-0.08 | 112.6% | |
| 31 Marzo 2025 | $-0.07 | $-0.10 | 29.6% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.29 | · | · | $0.62 | $0.76 | $1.10 | $1.10 | $-0.25 | $0.49 | $1.50 | · | $0.39 | |
| Revenue / Share | $0.14 | $0.10 | $0.01 | · | $0.00 | $0.22 | $2.76 | · | · | · | · | · | |
| Cash Flow / Share | $-0.19 | $-0.56 | $-0.73 | · | $-0.60 | $-1.29 | $0.97 | · | · | · | · | · | |
| Cash / Share | $0.09 | · | · | $0.24 | $0.43 | $0.89 | $0.34 | $0.76 | $0.58 | $0.45 | · | $0.19 | |
| EPS (TTM) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-0.12 | $-0.12 | · |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,294,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,570,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | · | · | $-64M | $-55M | $-45M | · | $-50M | · | $-31M | · | $-23M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | · | · | $100M | $99M | $100M | · | $99M | · | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | · | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | · | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | · | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | · | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | · | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | · | · | -21.7% | -15.5% | -16.7% | · | -21.6% | · | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | · | · | -40.8% | -25.1% | -25.7% | · | -35.6% | · | -35.3% | · | -16.7% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | · | · | 7.5 | 11.5 | 15.6 | · | 6.9 | · | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | · | · | 7.2 | 11.2 | 15.3 | · | 6.8 | · | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | · | -17.1 | · | -26.7 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | · | · | 0.1 | 0.4 | 0.0 | · | 0.0 | · | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | · | · | 1.1 | 1.0 | 1.3 | · | 0.9 | · | · | · | · |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.39 | $0.48 | · | $0.33 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.05 | · | $0.04 | $0.08 | · | · | $0.00 | $0.01 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.04 | · | · | · | · | · | · | · | $-0.22 | · | · | · | · | · | · | |
| Cash / Share | $0.09 | $0.09 | · | $0.14 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.15 | $-0.07 | · | $-0.18 | $-0.32 | $-0.50 | · | $-0.75 | $-0.78 | $-0.83 | · | $-0.77 | $-0.69 | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $70M | · | $71M | $58M | $31M | · | $5M | $4M | $2M | · | $531.0K | $408.0K | $126.0K | · | · | |
| Net Income TTM | $-61M | $-26M | · | $-69M | $-121M | $-177M | · | $-216M | $-202M | $-194M | · | $-158M | $-131M | $-110M | · | $-97M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -16.0 | -22.3 | · | -7.5 | -3.0 | -0.9 | · | -2.1 | -2.2 | -2.9 | · | -1.4 | -3.3 | · | · | · | |
| P/S | 25.9 | 9.5 | · | 7.0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 22.5 | 7.8 | · | 6.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -6.2% | -4.5% | · | -13.3% | -33.7% | -108.7% | · | -47.8% | -46.4% | -34.6% | · | -70.6% | -30.1% | · | · | · |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $50M | $31M | $1M | $139.0K | $298.0K |
| Margine Operativo % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Utile netto | $-50M | $-200M | $-177M | $-102M | $-88M |
| EPS Diluito | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.5 | 0.7 | 1.1 | · | 0.0 |
| Rapporto corrente | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-68M | $-180M | $-162M | $-90M | $-88M |
Proprietari istituzionali (13F) 167 filer · $890.0M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
167
Valore detenuto
$890.0M
Nuove posizioni
43
Posizioni chiuse
27
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 43 (+9 vs trimestre precedente) | 27 (+14 vs trimestre precedente) | 39 (-5 vs trimestre precedente) | 38 (+14 vs trimestre precedente) | +42.4M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Artal Group S.A. | $420.374.549 | 175.156.062 | 47,23% | Azioni |
| FMR LLC | $124.276.907 | 51.782.045 | 13,96% | Azioni |
| Siren, L.L.C. | $106.328.443 | 44.303.518 | 11,95% | Azioni |
| Sessa Capital IM, L.P. | $45.506.006 | 18.960.836 | 5,11% | Azioni |
| BlackRock, Inc. | $41.636.978 | 17.348.741 | 4,68% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.762.899 | 9.901.208 | 2,67% | Azioni |
| Point72 Asset Management, L.P. | $19.803.180 | 8.251.325 | 2,23% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $14.989.739 | 6.244.372 | 1,68% | Azioni |
| STATE STREET CORP | $11.802.646 | 4.917.769 | 1,33% | Azioni |
| VANGUARD GROUP INC | $11.047.532 | 9.606.549 | 1,24% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5.658.598 | 2.357.749 | 0,64% | Azioni |
| NORTHERN TRUST CORP | $4.724.686 | 1.968.619 | 0,53% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.696.260 | 1.956.775 | 0,53% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $3.922.970 | 1.634.571 | 0,44% | Azioni |
| CITADEL ADVISORS LLC | $3.842.837 | 1.601.182 | 0,43% | Azioni |
| CIBC Private Wealth Group LLC | $3.240.347 | 2.400.257 | 0,36% | Azioni |
| Ishara Investments LP | $3.050.400 | 1.271.000 | 0,34% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $2.722.150 | 1.134.229 | 0,31% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $2.704.800 | 1.127.000 | 0,30% | Azioni |
| MACKENZIE FINANCIAL CORP | $2.312.050 | 963.354 | 0,26% | Azioni |
| ADAR1 Capital Management, LLC | $1.800.000 | 750.000 | 0,20% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.672.262 | 696.776 | 0,19% | Azioni |
| UBS Group AG | $1.643.312 | 684.713 | 0,18% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.604.400 | 668.500 | 0,18% | Opzione Call |
| TWO SIGMA INVESTMENTS, LP | $1.544.266 | 643.444 | 0,17% | Azioni |
| Nuveen, LLC | $1.407.994 | 586.664 | 0,16% | Azioni |
| JANE STREET GROUP, LLC | $1.398.960 | 582.900 | 0,16% | Opzione Call |
| Bank of New York Mellon Corp | $1.364.893 | 568.706 | 0,15% | Azioni |
| Invesco Ltd. | $1.219.370 | 508.071 | 0,14% | Azioni |
| GOLDMAN SACHS GROUP INC | $1.165.310 | 485.546 | 0,13% | Azioni |
| Compagnie Lombard Odier SCmA | $1.152.000 | 480.000 | 0,13% | Azioni |
| BANK OF AMERICA CORP /DE/ | $1.011.117 | 421.299 | 0,11% | Azioni |
| BARCLAYS PLC | $929.960 | 387.483 | 0,10% | Azioni |
| CITADEL ADVISORS LLC | $886.320 | 369.300 | 0,10% | Opzione Call |
| XTX Topco Ltd | $858.905 | 357.877 | 0,10% | Azioni |
| CANADA PENSION PLAN INVESTMENT BOARD | $618.960 | 257.900 | 0,07% | Azioni |
| RHUMBLINE ADVISERS | $616.523 | 256.885 | 0,07% | Azioni |
| DEUTSCHE BANK AG\ | $594.068 | 247.528 | 0,07% | Azioni |
| WELLS FARGO & COMPANY/MN | $553.128 | 230.470 | 0,06% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $431.280 | 179.700 | 0,05% | Azioni |
| CITIGROUP INC | $420.492 | 175.205 | 0,05% | Azioni |
| GROUP ONE TRADING LLC | $420.031 | 175.013 | 0,05% | Azioni |
| Virtus Investment Advisers, LLC | $408.996 | 170.415 | 0,05% | Azioni |
| Headlands Technologies LLC | $401.275 | 167.198 | 0,05% | Azioni |
| Ikarian Capital, LLC | $395.218 | 164.674 | 0,04% | Azioni |
| Quarry LP | $374.846 | 156.186 | 0,04% | Azioni |
| MetLife Investment Management, LLC | $351.384 | 146.410 | 0,04% | Azioni |
| MORGAN STANLEY | $318.964 | 132.902 | 0,04% | Azioni |
| PANAGORA ASSET MANAGEMENT INC | $316.901 | 132.042 | 0,04% | Azioni |
| JPMORGAN CHASE & CO | $289.975 | 109.839 | 0,03% | Azioni |
Attivisti e proprietari del 5%+ 11 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 depositi | 08 Maggio 2026 | 39,40% | Modifica | · | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 depositi | 09 Dicembre 2024 | · | Deposito iniziale | · | SEC |
| 24 Febbraio 2012 | · | Deposito iniziale | · | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 Dicembre 2011 | · | Deposito iniziale | · | SEC |
| 14 Novembre 2011 | · | Deposito iniziale | · | SEC | |
| 15 Agosto 2011 | · | Deposito iniziale | · | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 Marzo 2010 | · | Deposito iniziale | Struttura del capitale | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 depositi | 05 Agosto 2005 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 08 Agosto 2003 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 18 Luglio 2003 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 19 Marzo 2003 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 49 insider · 32 dirigenti · 19 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 Febbraio 2026 M | 298.432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 Febbraio 2024 M | 1.098.068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 Febbraio 2014 M | 1.021.329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 Febbraio 2026 M | 105.356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 02 Giugno 2009 A | · | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 07 Febbraio 2008 A | 50.200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 08 Luglio 2024 A | 324.214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 Febbraio 2026 M | 31.264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 Febbraio 2026 M | 150.132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 Febbraio 2026 M | 277.945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 Febbraio 2026 M | 323.430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 Febbraio 2026 M | 93.869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 Febbraio 2026 M | 428.802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 Febbraio 2025 M | 76.368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 Febbraio 2025 M | 339.104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 Febbraio 2025 A | · | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 Febbraio 2024 M | 162.672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 08 Febbraio 2024 A | · | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 Febbraio 2023 M | 53.136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 Marzo 2021 M | 71.766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 Aprile 2020 F | 55.584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 Aprile 2020 F | 85.719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 02 Marzo 2015 M | 8.235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 Febbraio 2014 M | 278.703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 Febbraio 2010 A | · | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 Febbraio 2010 A | 27.306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 07 Febbraio 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 07 Febbraio 2008 A | 10.200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 07 Febbraio 2008 A | · | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 Febbraio 2007 A | · | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 Febbraio 2004 M | 15.000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 Gennaio 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Direttore | 03 Giugno 2026 M | 89.312 | 0 | 0 | $0 |
| Diane E. Sullivan | Direttore | 03 Giugno 2026 M | 126.122 | 0 | 0 | $0 |
| Judith L Swain | Direttore | 03 Giugno 2026 M | 174.486 | 0 | 0 | $0 |
| Amouyal Philippe | Direttore | 03 Giugno 2026 M | 374.486 | 0 | 0 | $0 |
| Sam L Barker | Direttore | 03 Giugno 2026 M | 213.771 | 0 | 0 | $0 |
| Christopher J Sobecki | Direttore | 03 Giugno 2026 M | 293.177 | 0 | 0 | $0 |
| Raymond Debbane | Direttore | 03 Giugno 2026 M | 1.995.498 | 7 | 0 | $723.048 |
| Robert J Lefkowitz MD | Direttore | 13 Maggio 2024 A | 48.364 | 0 | 0 | $0 |
| Frank Palantoni | Direttore | 21 Maggio 2023 M | 40.332 | 0 | 0 | $0 |
| Alan S Nies | Direttore | 21 Maggio 2023 M | 41.046 | 0 | 0 | $0 |
| Invus C.V. | Direttore | 31 Dicembre 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Direttore | 24 Aprile 2009 A | · | 0 | 0 | $0 |
| Clayton Stuart Rose | Direttore | 26 Giugno 2007 P | 25.000 | 0 | 0 | $0 |
| Barry Mills | Direttore | 26 Aprile 2007 A | 25.000 | 0 | 0 | $0 |
| Patricia M Cloherty | Direttore | 27 Aprile 2006 A | · | 0 | 0 | $0 |
| Thomas C Caskey | Direttore | 13 Ottobre 2005 P | 6.300 | 0 | 0 | $0 |
| Praveen Tyle | · | 28 Febbraio 2021 M | 120.791 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 16 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,81% | 161.882 NS | 31 Luglio 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0,45% | 40.310 NS | 31 Luglio 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,42% | 53.319 SH | 02 Ottobre 2026 | Giornaliero |
| IWC · iShares Trust | 0,12% | 842.323 SH | 11 Settembre 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 266.401 SH | 19 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | 0,03% | 2.343.443 SH | 11 Settembre 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1.432.882 SH | 19 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,02% | 118.391 NS | 31 Luglio 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 255.130 SH | 02 Ottobre 2026 | Giornaliero |
| IWM · iShares Trust | 0,02% | 6.319.224 SH | 11 Settembre 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2.594.934 SH | 19 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,01% | 637.561 SH | 19 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,01% | 17.992 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,00% | 85.389 SH | 03 Settembre 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 7.083.651 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 20.905 SH | 19 Agosto 2026 | Giornaliero |
LXRX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 11 analisti
COMPRA
Target mediano
$4.55
+150,0%
3 27,3%
Acquisto forte
5 45,5%
Compra
3 27,3%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
6 analisti · 2026-09-30Target medio $4.55 +149,8%
← Sotto tutti i target
Prezzo attuale $1.82
Basso$2.00
Media$4.55
Alto$8.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| APMD | · | · | · | · | · | · |
| SGP | · | · | · | · | 50.0% | · |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 6, 2026